The Shuman Law Firm Investigates Talecris Biotherapeutics Holdings Corp.

BOULDER, Colo.--(BUSINESS WIRE)-- The Shuman Law Firm today announced that it is investigating potential claims against the board of directors of Talecris Biotherapeutics Holdings Corp. (“Talecris” or the “Company”) (NASDAQ:TLCR) related to the Company’s agreement to be acquired by Grifols, S.A. (“Grifols”). The proposed cash-and-stock transaction is valued at approximately $3.4 billion.

Under the terms of the proposed merger agreement, Grifols will acquire all of the common stock of Talecris for $19.00 in cash and 0.641 newly issued non-voting Grifols' shares for each Talecris share. The deal values each Talecris share at approximately $26.16, based on the closing price of Grifols' ordinary shares as of June 4, 2010 and prevailing Euro-Dollar exchange rates. The proposed transaction is expected to be completed in the second half of 2010. In connection with the offer, the leading shareholders of Grifols have agreed to vote their shares in favor of the transaction, and an affiliate of Cerberus Capital Management, L.P., which owns approximately 49% of the outstanding Talecris common stock, has entered a similar agreement. The investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the transaction by Talecris’ board of directors.

If you currently own shares of Talecris and are interested in discussing your rights as a Talecris shareholder, or have information relating to this investigation, please contact Kip B. Shuman or Rusty E. Glenn toll-free at 866-974-8626 or email Mr. Shuman at [email protected] or Mr. Glenn at [email protected].

The Shuman Law Firm represents investors throughout the nation, concentrating its practice in securities class actions and shareholder derivative actions.



CONTACT:

The Shuman Law Firm
Kip B. Shuman, Esq., 866-974-8626
[email protected]
or
Rusty E. Glenn, Esq., 866-974-8626
[email protected]
Fax: 303-484-4886
www.shumanlawfirm.com

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Professional Services  Legal

MEDIA:

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.